Press Releases

04-12-2014

Eckert & Ziegler receives approval for gallium-68 generator for cost-effective diagnosis of cancer

06-11-2014

Eckert & Ziegler Q3/2014: Sales up, income mixed

24-10-2014

Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer

21-10-2014

Eckert & Ziegler awards prizes to young nuclear medicine researchers

16-10-2014

Development candidate SOMscan® against neuroendocrine tumors receives orphan drug status from the FDA

03-09-2014

Eckert & Ziegler takes over Brazilian isotope specialists – stronger presence in South America

05-08-2014

Eckert & Ziegler: Sales growth in first half of year, no growth in earnings so far

04-08-2014

Eckert & Ziegler: Cancer irradiation systems installed in Ethiopia for the first time

01-07-2014

Eckert & Ziegler: First patient enrolment for SOMscan®

27-06-2014

Eckert & Ziegler: European approval process for Gallium-68 generator successfully completed – world’s first authorization for new, inexpensive method for PET radiolabeling

06-05-2014

Eckert & Ziegler gets off to a positive start to the year

27-03-2014

Eckert & Ziegler fiscal year 2013: slight decrease in sales. Proposed dividend unchanged. Optimistic for fiscal year 2014.

25-03-2014 (Ad hoc press release)

Eckert & Ziegler to Recommend Dividend Payment

03-03-2014

Eckert & Ziegler Awards Travel Grants to Young Scientists in Nuclear Medicine

27-02-2014

Rare Disease Day: development candidate SOMscan® receives orphan drug status

28-01-2014 (Ad hoc press release)

Drop in Profits for 2013 Expected